Yingcong Tan, Cynthia Hubbard, Holly Owens, James Pitt, Christopher Giuliano, Bradley Haan, Thomas Breeden, Dumitru Sirbu, Kelsey Pena, Trevlyn Haddox, Stephanie B Edwin
{"title":"Xa因子抑制剂对低体重患者的疗效和安全性。","authors":"Yingcong Tan, Cynthia Hubbard, Holly Owens, James Pitt, Christopher Giuliano, Bradley Haan, Thomas Breeden, Dumitru Sirbu, Kelsey Pena, Trevlyn Haddox, Stephanie B Edwin","doi":"10.1002/phar.2888","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objective: </strong>The purpose of this study is to provide evidence for the safety and efficacy of factor Xa inhibitors in patients with a weight ≤60 kg or BMI < 18.5 kg/m<sup>2</sup> .</p><p><strong>Design: </strong>Multicenter, retrospective, cohort study.</p><p><strong>Setting: </strong>Twenty-two Ascension Health hospitals.</p><p><strong>Patients: </strong>Low-body-weight adult patients (weight ≤ 60 kg or BMI < 18.5 kg/m<sup>2</sup> ) receiving treatment for atrial fibrillation or venous thromboembolism.</p><p><strong>Intervention: </strong>Factor Xa inhibitors (apixaban or rivaroxaban) or warfarin.</p><p><strong>Measurements and main results: </strong>This study included 2538 patients between the factor Xa inhibitors (n = 1695) and warfarin (n = 843) groups with a mean weight of 53.5 ± 5.5 kg and BMI of 20.7 ± 3.1 kg/m<sup>2</sup> . No significant difference in time to major bleeding was noted after controlling for potential confounders (HR 1.03, 95% CI 0.70-1.53, p = 0.87); similar results were seen following propensity score matching. Thromboembolism (5.3% vs. 6.2%, p = 0.38), composite major + clinically relevant nonmajor bleeding (9.8% vs. 11.5%, p = 0.18), and all-cause mortality (10.7% vs. 12.8%, p = 0.12) were similar between patients receiving factor Xa inhibitors versus warfarin.</p><p><strong>Conclusion: </strong>No differences in safety or effectiveness were noted between factor Xa inhibitors versus warfarin. These findings provide encouraging evidence to support the use of factor Xa inhibitors in low-body-weight patients.</p>","PeriodicalId":20013,"journal":{"name":"Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of factor Xa inhibitors in low body weight patients.\",\"authors\":\"Yingcong Tan, Cynthia Hubbard, Holly Owens, James Pitt, Christopher Giuliano, Bradley Haan, Thomas Breeden, Dumitru Sirbu, Kelsey Pena, Trevlyn Haddox, Stephanie B Edwin\",\"doi\":\"10.1002/phar.2888\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Study objective: </strong>The purpose of this study is to provide evidence for the safety and efficacy of factor Xa inhibitors in patients with a weight ≤60 kg or BMI < 18.5 kg/m<sup>2</sup> .</p><p><strong>Design: </strong>Multicenter, retrospective, cohort study.</p><p><strong>Setting: </strong>Twenty-two Ascension Health hospitals.</p><p><strong>Patients: </strong>Low-body-weight adult patients (weight ≤ 60 kg or BMI < 18.5 kg/m<sup>2</sup> ) receiving treatment for atrial fibrillation or venous thromboembolism.</p><p><strong>Intervention: </strong>Factor Xa inhibitors (apixaban or rivaroxaban) or warfarin.</p><p><strong>Measurements and main results: </strong>This study included 2538 patients between the factor Xa inhibitors (n = 1695) and warfarin (n = 843) groups with a mean weight of 53.5 ± 5.5 kg and BMI of 20.7 ± 3.1 kg/m<sup>2</sup> . No significant difference in time to major bleeding was noted after controlling for potential confounders (HR 1.03, 95% CI 0.70-1.53, p = 0.87); similar results were seen following propensity score matching. Thromboembolism (5.3% vs. 6.2%, p = 0.38), composite major + clinically relevant nonmajor bleeding (9.8% vs. 11.5%, p = 0.18), and all-cause mortality (10.7% vs. 12.8%, p = 0.12) were similar between patients receiving factor Xa inhibitors versus warfarin.</p><p><strong>Conclusion: </strong>No differences in safety or effectiveness were noted between factor Xa inhibitors versus warfarin. These findings provide encouraging evidence to support the use of factor Xa inhibitors in low-body-weight patients.</p>\",\"PeriodicalId\":20013,\"journal\":{\"name\":\"Pharmacotherapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/phar.2888\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/phar.2888","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Efficacy and safety of factor Xa inhibitors in low body weight patients.
Study objective: The purpose of this study is to provide evidence for the safety and efficacy of factor Xa inhibitors in patients with a weight ≤60 kg or BMI < 18.5 kg/m2 .
Design: Multicenter, retrospective, cohort study.
Setting: Twenty-two Ascension Health hospitals.
Patients: Low-body-weight adult patients (weight ≤ 60 kg or BMI < 18.5 kg/m2 ) receiving treatment for atrial fibrillation or venous thromboembolism.
Intervention: Factor Xa inhibitors (apixaban or rivaroxaban) or warfarin.
Measurements and main results: This study included 2538 patients between the factor Xa inhibitors (n = 1695) and warfarin (n = 843) groups with a mean weight of 53.5 ± 5.5 kg and BMI of 20.7 ± 3.1 kg/m2 . No significant difference in time to major bleeding was noted after controlling for potential confounders (HR 1.03, 95% CI 0.70-1.53, p = 0.87); similar results were seen following propensity score matching. Thromboembolism (5.3% vs. 6.2%, p = 0.38), composite major + clinically relevant nonmajor bleeding (9.8% vs. 11.5%, p = 0.18), and all-cause mortality (10.7% vs. 12.8%, p = 0.12) were similar between patients receiving factor Xa inhibitors versus warfarin.
Conclusion: No differences in safety or effectiveness were noted between factor Xa inhibitors versus warfarin. These findings provide encouraging evidence to support the use of factor Xa inhibitors in low-body-weight patients.
期刊介绍：
Pharmacotherapy is devoted to publication of original research articles on all aspects of human pharmacology and review articles on drugs and drug therapy. The Editors and Editorial Board invite original research reports on pharmacokinetic, bioavailability, and drug interaction studies, clinical trials, investigations of specific pharmacological properties of drugs, and related topics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
